{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:05:34Z","timestamp":1781568334038,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To find pharmacokinetic\/pharmacodynamic parameters of vancomycin associated with the optimal outcome of severe infection due to <jats:italic>Enterococcus<\/jats:italic> species.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed enterococcal bacteremia cases treated with vancomycin from January 2015 to December 2020. The primary outcome was 30-day mortality. We calculated cutoff values of the ratio of vancomycin area under the concentration\u2013time curve over 24\u00a0h to the minimum inhibitory concentration (AUC<jats:sub>24<\/jats:sub>\/MIC) and trough concentration (C<jats:sub>trough<\/jats:sub>) during the initial 72\u00a0h of treatment. The optimal cutoff value was determined using the Youden index. Binary variables created based on these cutoffs were further assessed using multivariable analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 65 patients were included. The majority (87.7%) had solid or hematologic malignancies. Thirty-day mortality and nephrotoxicity occurred in nine (13.4%) and 14 (21.5%) patients, respectively. Both vancomycin AUC<jats:sub>24<\/jats:sub>\/MIC and C<jats:sub>trough<\/jats:sub> showed fair performance in predicting 30-day mortality (AUC of receiver-operator curve for AUC<jats:sub>24<\/jats:sub>\/MIC, 0.712; 95% confidence interval [CI] 0.539\u20130.886; AUC for C<jats:sub>trough<\/jats:sub>, 0.760; 95% CI 0.627\u20130.892; pairwise AUC comparison: p\u2009=\u20090.570). C<jats:sub>trough<\/jats:sub>\u2009\u2265\u200913.94\u00a0\u03bcg\/mL, but not AUC<jats:sub>24<\/jats:sub>\/MIC\u2009\u2265\u2009504, had a significant association with 30-day mortality after adjusting for confounders (odds ratio, 8.40; 95% CI 1.60\u201386.62; p\u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Mean C<jats:sub>trough<\/jats:sub>\u2009\u2265\u200913.94\u00a0\u03bcg\/mL during the initial 72\u00a0h was associated with higher 30-day mortality in enterococcal bacteremia. Further studies are warranted to elucidate optimal pharmacokinetic targets for enterococcal bacteremia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07668-w","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:02:55Z","timestamp":1660104175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic\/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-4863","authenticated-orcid":false,"given":"Eliel","family":"Nham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-3964","authenticated-orcid":false,"given":"Kyungmin","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-2547","authenticated-orcid":false,"given":"You Min","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-0224","authenticated-orcid":false,"given":"Hyo Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Young","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9490-6609","authenticated-orcid":false,"given":"Jae-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-2369","authenticated-orcid":false,"given":"Sun Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-4459","authenticated-orcid":false,"given":"Cheol-In","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-101X","authenticated-orcid":false,"given":"Doo Ryeon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-7561","authenticated-orcid":false,"given":"Hee Jae","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-773X","authenticated-orcid":false,"given":"Hyung-Doo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-0145","authenticated-orcid":false,"given":"Nam Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-9780","authenticated-orcid":false,"given":"Kyong Ran","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"issue":"10","key":"7668_CR1","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s00520-011-1353-z","volume":"20","author":"CI Kang","year":"2012","unstructured":"Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, et al. Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer. 2012;20(10):2371\u20138.","journal-title":"Support Care Cancer"},{"issue":"1","key":"7668_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13756-020-00770-1","volume":"9","author":"X Zhou","year":"2020","unstructured":"Zhou X, Willems RJL, Friedrich AW, Rossen JWA, Bathoorn E. Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics. Antimicrob Resist Infect Control. 2020;9(1):130.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"7668_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrmicro2761","volume":"10","author":"CA Arias","year":"2012","unstructured":"Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266\u201378.","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"7668_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"7668_CR5","doi-asserted-by":"publisher","first-page":"e01602-17","DOI":"10.1128\/AAC.01602-17","volume":"62","author":"MTB Jumah","year":"2018","unstructured":"Jumah MTB, Vasoo S, Menon SR, De PP, Neely M, Teng CB. Pharmacokinetic\/pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia. Antimicrob Agents Chemother. 2018;62(3):e01602-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"7668_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40780-019-0138-2","volume":"5","author":"I Nakakura","year":"2019","unstructured":"Nakakura I, Sakakura K, Imanishi K, Sako R, Yamazaki K. Association between vancomycin pharmacokinetic\/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study. J Pharm Health Care Sci. 2019;5:8.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"7668_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1186\/s12879-021-06809-x","volume":"21","author":"Y Sohn","year":"2021","unstructured":"Sohn Y, Rim JH, Cho Y, Hyun J, Baek Y, Kim M, et al. Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species. BMC Infect Dis. 2021;21(1):1099.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"7668_CR8","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/pharmaceutics13091378","volume":"13","author":"W Katip","year":"2021","unstructured":"Katip W, Oberdorfer P. A monocentric retrospective study of AUC\/MIC ratio of vancomycin associated with clinical outcomes and nephrotoxicity in patients with Enterococcal infections. Pharmaceutics. 2021;13(9):1378.","journal-title":"Pharmaceutics"},{"issue":"2","key":"7668_CR9","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1093\/cid\/ciy680","volume":"67","author":"X Liang","year":"2018","unstructured":"Liang X, Fan Y, Yang M, Zhang J, Wu J, Yu J, et al. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin Infect Dis. 2018;67(2):S249\u201355.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"7668_CR10","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384.","journal-title":"Nephron Clin Pract"},{"key":"7668_CR11","doi-asserted-by":"crossref","unstructured":"Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19\u201362.","DOI":"10.1038\/kisup.2012.64"},{"issue":"5","key":"7668_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"1","key":"7668_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","volume":"11","author":"JW Chow","year":"1999","unstructured":"Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999;11(1):7\u201312.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"7668_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"7668_CR15","unstructured":"Performance Standards for Antimicrobial Susceptibility Testing. 31th ed. CLSI supplement M100. Wayne: Clinical & Laboratory Standards Institute; 2020."},{"key":"7668_CR16","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. Clinical and Laboratory Standards Institute; 2018."},{"issue":"4","key":"7668_CR17","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/AAC.01485-12","volume":"57","author":"NE Holmes","year":"2013","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O\u2019Sullivan MV, et al. Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"7668_CR18","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/AAC.03970-14","volume":"59","author":"AM Casapao","year":"2015","unstructured":"Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"7668_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/antibiotics9100672","volume":"9","author":"T Chattaweelarp","year":"2020","unstructured":"Chattaweelarp T, Changpradub D, Punyawudho B, Thunyaharn S, Santimaleeworagun W. Is early monitoring better? Impact of early vancomycin exposure on treatment outcomes and nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics (Basel). 2020;9(10):672.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"7668_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"1","key":"7668_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27\u201338.","journal-title":"Biometrika"},{"issue":"5","key":"7668_CR22","doi-asserted-by":"publisher","first-page":"e02535-16","DOI":"10.1128\/AAC.02535-16","volume":"61","author":"R Chavada","year":"2017","unstructured":"Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC (0\u201324) threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;61(5):e02535-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"7668_CR23","doi-asserted-by":"publisher","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","volume":"62","author":"EJ Zasowski","year":"2018","unstructured":"Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62(1):e01684-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"7668_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734\u201344.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"7668_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309\u201316.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07668-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T04:04:25Z","timestamp":1660104265000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07668-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7668"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07668-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Samsung Medical Center (IRB No: 2021-09-032) and carried out in accordance with relevant guidelines and regulations.The requirement of informed consent was waived by the Institutional Review Board of Samsung Medical Center (IRB No: 2021-09-032).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"686"}}